My Trial With Sanofi ' s Admelog, The Biosimilar Version of Humalog

A while back Iblogged about the emergence of biosimilar insulin in the U.S., more than a decade after I studied the topic and discovered some troubling reasons none existed. Since then, in spite of top officials at the U.S. Department of Health and Human Services advocating for a more robust biosimilars market in the U.S., we have seen fewer rather than more, so that ' s not working out so well for the Trump Administration ' s promise to bring drug prices way down so far. In late 2018, Merck quietly pulled the plug on its own Lantus biosimilar which was to be branded as Lusduna Nexvue (see moreHERE for details). Merck tried to keep its plan to dump its Lantus biosimilar on the down-low, but news emerged from a South Korean securities filing (akin to the U.S. SEC) when co-development partner Samsung Bioepis disclosed the fact that Merck was paying it a termination fee in its filings with Korean regulators.Anyway, I ' ve been using theHumalog biosimilar branded asAdmelog (U-100 insulin lispro rDNA origin) made by Sanofi for the past few weeks. I use vials and syringes since is the least costly way of buying insulin these days. The reason is purely economic: while still paying towards my insurance deductible, I have the option of paying more than $230 for a single vial of Humalog insulin, or I can pay just $99 for the same insulin with a coupon from Sanofi. Insulin pens cost even more than vials do, and you get less insulin in five pens than you do in a single vial of ...
Source: Scott's Web Log - Category: Endocrinology Tags: Eli Lilly and Company follow-on insulin analogs 2019 Admelog biosimilars generics Humalog insulin prices Medicare Sanofi Source Type: blogs